📰 Quotient Sciences News

Page 12 - Quotient Sciences News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Quotient Sciences. Real-time updates on events, politics, business and more.

South Rampart Pharma Receives Year 3 of NIH Fast-Track STTR Commercialization Grant

September 23, 2022

South Rampart Pharma Receives Year 3 of NIH Fast-Track STTR Commercialization Grant - read this article along with other careers information, tips and advice on BioSpace

United States Williamk Schmidt Gideon Broshy Maxim Jacobs Hernan Bazan Neuroscience Center

Source: biospace.com

South Rampart Pharma Receives Year 3 of NIH Fast-Track STTR Commercialization Grant

September 22, 2022

/PRNewswire/ -- South Rampart Pharma ("South Rampart" or the "Company"), a clinical-stage life science company advancing innovative medications for the...

United States Williamk Schmidt Gideon Broshy Maxim Jacobs Hernan Bazan Neuroscience Center

Source: prnewswire.com

Quotient Sciences Expands UK Facilities to Support the Delivery of Translational Pharmaceutics® Programs

September 22, 2022

/PRNewswire/ -- Quotient Sciences, a drug development and manufacturing accelerator, has completed major investments and expansions at its Nottingham, UK and...

United Kingdom Mark Egerton Company Nottingham Prnewswire Quotient Sciences Drug Administration Quotient Sciences

Source: prnewswire.com

Quotient Sciences Global News: Quotient Sciences Expands UK Facilities to Support the Delivery of Translational Pharmaceutics Programs

September 22, 2022

Company increases laboratory and clinical capacity to meet demand for fully integrated drug development capabilities NOTTINGHAM, England, Sept. 22, 2022 /PRNewswire/ -- Quotient Sciences

United Kingdom Kostenloser Wertpapierhandel Mark Egerton Company Nottingham Prnewswire Quotient Sciences Drug Administration

Source: finanznachrichten.de

Ensysce Biosciences Inc: Ensysce Biosciences and Quotient Sciences Announce a Partnership on the Development and Clinical Testing of Ensysce's PF614-MPAR, a Novel Opioid Designed to Prevent Abuse and Overdose

August 31, 2022

Partnership further expedites Ensysce's development pipeline NOTTINGHAM, England, Aug. 31, 2022 /PRNewswire/ -- Ensysce Biosciences, Inc., a clinical-stage biotech company applying transformative

Mark Egerton Lynn Kirkpatrick Ensysce Biosciences Prnewswire Ensysce Biosciences Inc Quotient Sciences Translational Pharmaceutics

Source: finanznachrichten.de

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Ensysce Biosciences and Quotient Sciences Announce a Partnership on the Development and Clinical Testing of Ensysce's PF614-MPAR, a Novel Opioid Designed to Prevent Abuse and Overdose

August 31, 2022

/PRNewswire/ -- Ensysce Biosciences, Inc., a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety, and Quotient...

Mark Egerton Lynn Kirkpatrick Ensysce Biosciences Prnewswire Ensysce Biosciences Inc Quotient Sciences Translational Pharmaceutics

Source: prnewswire.com

Non-Clinical vs Clinical: Risks & Considerations When Developing Modified Release Dosage Forms, Upcoming Webinar Hosted by Xtalks

August 29, 2022

Toronto, ON (PRWEB) August 29, 2022 -- Oral modified release drug products remain highly prevalent in drug development pipelines. These dosage forms tailor

United Kingdom Vanessa Zann Vera Kovacevic Honeycomb Worldwide Inc Quotient Sciences Senior Drug Development Consultant

Source: prweb.com